{
}
Novartis is set to close its sites in Munich and Boston, resulting in the loss of 330 jobs, following its $2.9 billion acquisition of MorphoSys. The closures are expected to be completed by the end of 2025. This move comes as Novartis continues to expand its oncology portfolio and engage in various licensing deals.
BioAge Labs has entered a multi-year partnership with Novartis to tackle age-related diseases, potentially worth up to $550 million. The collaboration will leverage BioAge's human longevity datasets and Novartis's expertise in exercise biology to discover new therapeutic targets and explore the biological mechanisms of aging. This agreement follows BioAge's recent IPO and the discontinuation of a phase 2 obesity trial due to safety concerns.
BioAge Labs shares surged 14% to $4.67 following a research collaboration with Novartis, potentially worth up to $550 million. The partnership will explore aging-related diseases and the impact of physical exercise on longevity, combining BioAge's datasets with Novartis's expertise. BioAge will receive initial funding and milestone payments, with both companies able to pursue novel targets identified during the collaboration.
BioAge Labs has announced a multi-year collaboration with Novartis to discover novel therapeutic targets for age-related diseases, leveraging BioAge's extensive human longevity data and Novartis's expertise in exercise biology. The partnership includes up to $20 million in upfront payments and research funding, with potential future milestones totaling up to $530 million. This collaboration aims to explore the biological mechanisms of aging and the benefits of physical exercise to develop transformative therapies.
Novartis has partnered with BioAge Labs in a multi-year collaboration to discover new therapies for age-related diseases, involving up to $20 million in funding and potential milestones of $530 million. The partnership will leverage BioAge’s extensive human longevity datasets and advanced analytics to identify healthy lifespan determinants. This collaboration comes after BioAge faced a setback with its lead asset, azelaprag, which was discontinued due to safety concerns in a recent study.
AbbVie's schizophrenia drug emraclidine failed two mid-phase trials, performing no better than placebo, resulting in a $40 billion market cap loss for the company. This setback follows the recent approval of Bristol Myers Squibb's Cobenfy, the first new schizophrenia drug in decades, which boosted BMS's share price by 12%. The failure raises concerns for other companies developing similar drugs in the same class.
BioAge Labs has halted its mid-stage study of the obesity drug azelaprag due to safety concerns after participants showed elevated liver enzymes, leading to a 75% drop in share price. The company plans to provide an update on azelaprag's development in early 2025, while also pursuing another program targeting central nervous system disorders.
Biopharma IPOs are experiencing a surge, with companies like Septerna and Ceribell achieving significant post-IPO price increases. This success is raising hopes that more tech-related firms will follow suit, as venture capital and hedge fund investments in these biopharma companies remain strong.
BioAge Labs, Inc.
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Novartis to close MorphoSys sites in Boston and Munich cutting 330 jobs
16:30 19.12.2024
novartis and bioage partner to tackle age-related diseases in major deal
United States Dollar
Novartis AG
Amgen Inc.
BioAge Labs, Inc.
Eli Lilly and Company
USA
CHE
Lai Peng Leong
Michaela Kneissel
Kristen Fortney
Show more
16:44 18.12.2024
bioage partners with novartis in research collaboration worth up to 550 million
16:37 18.12.2024
bioage labs partners with novartis to target age-related diseases through research
15:11 18.12.2024
novartis partners with bioage labs to explore therapies for age-related diseases
14:45 18.12.2024
setbacks in drug development impact schizophrenia and oncology markets
Arcus Biosciences, Inc.
Hoffmann-La Roche AG
Gilead Sciences, Inc.
Biohaven Ltd.
Merck & Co., Inc.
Genentech
Cassava Sciences, Inc.
ABBVIE
Bristol-Myers Squibb Co
BioAge Labs, Inc.
USA
Jean Rochefort
Show more
01:00 16.12.2024
BioAge Labs Halts Obesity Drug Study Shares Plummet Due to Safety Concerns
United States Dollar
BioAge Labs, Inc.
Novo Nordisk A/S
Eli Lilly and Company
Amgen Inc.
USA
Kristen Fortney
Show more
01:00 07.12.2024
biopharma ipo success sparks hopes for tech sector public offerings
United States Dollar
Upstream Bio, Inc.
Septerna, Inc.
CeriBell, Inc.
MBX Biosciences, Inc.
BioAge Labs, Inc.
Zenas BioPharma, Inc.
Bicara Therapeutics Inc.
Cormorant Asset Management
Redmile Group
RA Capital Management
OrbiMed Advisors
Deep Track Biotechnology Master Fund
Show more
20:15 31.10.2024
Trending
Subcategory
Industry Trends
Corporate News
Supply Chain Management
Global Trade Developments
Startups & Entrepreneurship
Government Economic Policies
Industry Mergers & Acquisitions
Retail and Consumer Goods
Finance Mergers & Acquisitions
Financial Scams and Security
Fintech Startups
Emerging Startups
Workplace Trends
CEO Changes
Venture Capital Investments
Cryptocurrency Trends
Funding Rounds & Investments
Energy Sector Developments
Market Analysis and Predictions
Stock Market Updates
Countries:
Companies:
Apple Inc.
Google Inc.
NVIDIA Corporation
Delhivery Limited
Ecom Express Ltd.
Alphabet Inc.
OpenAI ERC USD
Ciscom Corp.
ERICSSON - CLASS B
Physicswallah Ltd.
Learning Resources Inc.
MGA Entertainment Inc.
State Street Global Advisors Luxembourg SICAV - SSGA EMU ESG Screened Equity Fund
Snap Inc.
Tiktok USD
Semiconductor Manufacturing International Corporation
Hua Hong Semiconductor Ltd.
Spotify Technology S.A.
Dropbox, Inc.
Vimeo, Inc.
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Euro
United Arab Emirates Dirham
Vietnamese Đồng
New Taiwan Dollar
Russian Ruble
South Korean Won
Pakistani Rupee
Algerian Dinar
Australian Dollar
Thai Baht
Japanese Yen
Saudi Riyal
People:
Donald Trump
Ilya Sutskever
Peter Thiel
Amal El Fallah Seghrouchni
Trixie Lohmirmand
Scott Bessent
Jamieson Greer
Joe Jurken
Stephen Roachford
David French
Rick Woldenberg
Marc Rosenberg
Isaac Larian
Hichem Djouhri
Laurina Emmanuel
Tim Cook
Andrew Ferguson
Sheryl Sandberg
Mark Zuckerberg
Pavel Prass